Fluoxetine added to immunotherapy for advanced liver and gallbladder cancer with depression or anxiety

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional study enrolls adults with advanced hepatocellular carcinoma or cholangiocarcinoma who screen positive for depression or anxiety and are starting first-line PD-1/PD-L1 therapy. Participants will receive either fluoxetine or a matching placebo in addition to planned immunotherapy, with regular imaging and clinical visits to monitor tumor response, survival, and mood symptoms. Key eligibility includes measurable disease, ECOG 0–2, Child-Pugh score ≤7, and adequate blood counts and chemistry. Outcomes will compare tumor control and survival between the fluoxetine and placebo groups while also tracking changes in depression and anxiety scores.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: 18 to 80 years old, both male and female are acceptable.
* The histopathological/cytological diagnosis is hepatocellular carcinoma or cholangiocarcinoma. Hepatocellular carcinoma can be diagnosed by imaging.
* Patients with metastatic advanced or locally advanced liver and gallbladder malignancies;
* No treatment has been received and a first-line treatment regimen including PD-1 inhibitors /PD-L1 inhibitors is planned to be carried out;
* Patients with a PHQ-9 score of ≥10 or a GAD-7 score of ≥8, that is, those with positive screening for depression or anxiety;
* At least one lesion measurable by CT or MRI (with a maximum diameter of ≥0.5cm);
* ECOG: 0-2;
* Child-Pugh score ≤7 points;
* The expected survival period is ≥12 weeks.
* Baseline blood cell count tests and blood biochemistry must meet the following standards:1) White blood cell count ≥3.0×10\^9/L; Hemoglobin ≥90 g/L;2) Absolute neutrophil count ≥1.5×10\^9/L;3) Platelet count ≥100×10\^9/L;4) Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of the normal upper limit (ULN);5) Total bilirubin ≤ twice ULN;6) Serum creatinine ≤ 1.5 times ULN; Albumin ≥30 g/L;
* The subjects voluntarily joined this study, signed the informed consent form, had good compliance and cooperated with the follow-up.

Exclusion Criteria:

* Those with uncorrectable coagulation dysfunction and a distinct bleeding tendency;
* Patients who currently have unstable or active ulcers or gastrointestinal bleeding;
* Severe functional insufficiency of vital organs, such as severe cardiopulmonary insufficiency, etc;
* Patients with hepatic encephalopathy or intractable ascites requiring treatment;
* A history of mental disorders such as bipolar disorder, schizophrenia, and active suicidal ideation;
* Patients with active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (active is defined as a viral load \> 20,000 IU/mL), or those who are positive for HBV or HCV and refuse to receive standardized antiviral treatment;
* Unable to swallow oral medication;
* Patients allergic to fluoxetine;
* Currently using drugs that may have serious interactions with fluoxetine;
* The researchers assessed that the patient was unable or unwilling to comply with the requirements of the research protocol.

Where it's running

• First Affiliated Hospital of Wenzhou Medical University
  Wenzhou, Zhejiang, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-COA®: using AI to measure depression and anxiety severity from video interviews

  This will test whether an AI tool can reliably measure depression and anxiety severity from video interviews in adults who have just started a new treatment.

  Recruiting Deliberate Solutions Inc. · Houston, Texas · NCT06923995

• Improving patient engagement in collaborative care for anxiety and depression

  This study is testing a new way to involve patients more in their anxiety and depression treatment by using their personal goals to see if it makes them and their doctors happier with the care they receive.

  Recruiting at 6 sites Dartmouth-Hitchcock Medical Center · Concord, New Hampshire and 5 other locations · NCT06898593

• Understanding anxiety, depression, and bipolar disorder over time in China

  This study tests how anxiety, depressive, and bipolar symptoms change over three years to find patterns that help with earlier recognition and prediction in people aged 12–55.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07903246

• See if personalized CBM-I can help anxious kids ages 10–17

  Aimed at youth with Generalized, Separation, or Social Anxiety, the study tests a personalized cognitive bias modification for interpretation (CBM-I) to see if it reduces threat-focused thinking and anxiety.

  Recruiting University of Denver · Denver, Colorado · NCT07818876

• Expectancy Focused Exposure for Anxiety Disorders

  We test whether Expectancy Focused Exposure helps reduce anxiety symptoms and prevent fear from coming back better than Anxiety Focused Exposure in adults with anxiety disorders.

  Recruiting University of Chile · Santiago, Santiago Metropolitan · NCT07753330

• Does extra family income improve child mental health and brain biology in low-income families?

  This study tests whether three years of extra income for parents can improve their child’s mental health and neuroimmune function.

  Recruiting Northwestern University · Evanston, Illinois · NCT07641244

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.